TipRanks (Thu, 25-Jun 7:25 AM ET)
Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild Itself
Globe Newswire (Thu, 18-Jun 12:42 PM ET)
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
Globe Newswire (Tue, 16-Jun 10:30 AM ET)
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
Globe Newswire (Tue, 9-Jun 8:30 AM ET)
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
Globe Newswire (Fri, 22-May 11:30 AM ET)
Vericel Raises 2026 Guidance After Record Revenue Growth and Margin Expansion
Market Chameleon (Thu, 7-May 5:13 AM ET)
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Globe Newswire (Thu, 7-May 7:45 AM ET)
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
Globe Newswire (Thu, 23-Apr 8:31 AM ET)
MediWound Reports BARDA Contract Award to Vericel for NexoBrid Valued at up to $197 Million
Globe Newswire (Thu, 2-Apr 3:26 PM ET)
Globe Newswire (Thu, 2-Apr 2:40 PM ET)
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Vericel trades on the NASDAQ stock market under the symbol VCEL.
As of June 25, 2026, VCEL stock price climbed to $42.90 with 532,216 million shares trading.
VCEL has a beta of 1.19, meaning it tends to be more sensitive to market movements. VCEL has a correlation of 0.11 to the broad based SPY ETF.
VCEL has a market cap of $2.19 billion. This is considered a Mid Cap stock.
Last quarter Vericel reported $68 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.03.
In the last 3 years, VCEL traded as high as $63.00 and as low as $28.95.
The top ETF exchange traded funds that VCEL belongs to (by Net Assets): IJR, VTI, IWM, XBI, SPSM.
VCEL has underperformed the market in the last year with a return of -1.0%, while SPY returned +22.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VCEL shares. However, VCEL has outperformed the market in the last 3 month and 2 week periods, returning +29.7% and +14.8%, while SPY returned +12.7% and +1.5%, respectively. This indicates VCEL has been having a stronger performance recently.
VCEL support price is $40.51 and resistance is $42.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VCEL shares will trade within this expected range on the day.